ES2099257T3 - Nueva variante gp 160 no hendible, soluble, de forma hibrida. - Google Patents

Nueva variante gp 160 no hendible, soluble, de forma hibrida.

Info

Publication number
ES2099257T3
ES2099257T3 ES92910881T ES92910881T ES2099257T3 ES 2099257 T3 ES2099257 T3 ES 2099257T3 ES 92910881 T ES92910881 T ES 92910881T ES 92910881 T ES92910881 T ES 92910881T ES 2099257 T3 ES2099257 T3 ES 2099257T3
Authority
ES
Spain
Prior art keywords
hiv
region
strain
soluble
hendible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910881T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2099257T3 publication Critical patent/ES2099257T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE EN PARTICULAR A UN NUEVO METODO PARA CONSTRUIR UNA CASSETTE DE EXPRESION QUE CELDA DE EXPRESION QUE COMPRENDE UNA UNIDAD DE ADN QUE CODIFICA UN PRECURSOR DE UNA VARIANTE DE GP160 HIBRIDA, NO PARTIBLE Y SOLUBLE, ASI COMO A LA NUEVA VARIANTE MENCIONADA ANTERIORMENTE.
ES92910881T 1991-05-02 1992-04-30 Nueva variante gp 160 no hendible, soluble, de forma hibrida. Expired - Lifetime ES2099257T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR919105392A FR2676071B1 (fr) 1991-05-02 1991-05-02 Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Publications (1)

Publication Number Publication Date
ES2099257T3 true ES2099257T3 (es) 1997-05-16

Family

ID=9412448

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910881T Expired - Lifetime ES2099257T3 (es) 1991-05-02 1992-04-30 Nueva variante gp 160 no hendible, soluble, de forma hibrida.

Country Status (12)

Country Link
US (2) US6261799B1 (es)
EP (1) EP0541753B1 (es)
JP (1) JP3453611B2 (es)
AT (1) ATE149203T1 (es)
CA (1) CA2086509C (es)
DE (1) DE69217614T2 (es)
DK (1) DK0541753T3 (es)
ES (1) ES2099257T3 (es)
FR (1) FR2676071B1 (es)
GR (1) GR3023070T3 (es)
SG (1) SG44828A1 (es)
WO (1) WO1992019742A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59309207D1 (de) * 1992-10-06 1999-01-21 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
WO1994016081A1 (de) * 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
CA2834288A1 (en) * 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
EP2869842A1 (en) * 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
EP3504225B1 (en) 2017-11-17 2024-04-24 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
ATE125157T1 (de) * 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.

Also Published As

Publication number Publication date
CA2086509C (fr) 2003-07-01
JP3453611B2 (ja) 2003-10-06
GR3023070T3 (en) 1997-07-30
DE69217614D1 (de) 1997-04-03
CA2086509A1 (fr) 1992-11-03
JPH05508324A (ja) 1993-11-25
WO1992019742A1 (fr) 1992-11-12
US6261799B1 (en) 2001-07-17
FR2676071B1 (fr) 1994-11-18
DK0541753T3 (da) 1997-08-04
EP0541753B1 (fr) 1997-02-26
DE69217614T2 (de) 1997-07-10
US6284248B1 (en) 2001-09-04
ATE149203T1 (de) 1997-03-15
FR2676071A1 (fr) 1992-11-06
EP0541753A1 (fr) 1993-05-19
SG44828A1 (en) 1997-12-19

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2099257T3 (es) Nueva variante gp 160 no hendible, soluble, de forma hibrida.
WO1993018055A3 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
EP0255190A3 (en) Recombinant polypeptides and their uses, inclusing assay for aids virus
DE69231705T2 (de) Gag-Env Fusion-Antigen aus HIV
WO1995016040A3 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
GB2336844A (en) Anti-hiv peptides and proteins
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DK0462551T3 (da) Monoklonale antistoffer mod HIV gp120
EP1013766A3 (en) Peptides for the detection of HIV-1-Group O
Ivanoff et al. Human immunodeficiency virus antigen.
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
DK284389D0 (da) Precursorantigener
EP0288093A3 (en) Strips containing the gp160 envelope protein of the aids virus/hiv, and its use in the detection of the aids antibody
ES2009280A6 (es) Un metodo para detectar anticuerpos al virus hiv-1 en una muestra.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 541753

Country of ref document: ES